There are 2789 resources available
268P - Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]
Presenter: Andreas Wicki
Session: ePoster Display
269P - Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
Presenter: Hope Rugo
Session: ePoster Display
270P - Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Presenter: Seock-Ah Im
Session: ePoster Display
271P - First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Presenter: Ye Guo
Session: ePoster Display
272P - Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)
Presenter: Miguel Martin
Session: ePoster Display
274P - Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Efficacy and safety results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study
Presenter: Thibault De La Motte Rouge
Session: ePoster Display
276P - Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: Interim results of a phase II trial
Presenter: Min Yan
Session: ePoster Display
277P - Phase II randomized study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with HR-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B
Presenter: Hiroko Masuda
Session: ePoster Display